The IPO removes near-term financing overhang and funds the pipeline through key Phase 2b/3 readouts in 2027. However, as a pre-revenue clinical-stage biotech with no approved products and mounting losses, the stock will trade on clinical data catalysts (MIST Phase 2b AP01 data H2 2027, AURA Phase 2 AP02 data late 2027). Monitor enrollment updates and any early efficacy signals. The 180-day lock-up on insider shares expires ~October 2026, creating potential overhang.
Executive Summary
Avalyn Pharma priced its IPO of 16,666,667 shares at $18.00 per share, raising approximately $300 million in gross proceeds ($279 million net before expenses). The offering provides a cash runway into 2029 to fund Phase 2b/3 development of inhaled pirfenidone (AP01) and nintedanib (AP02) for pulmonary fibrosis. This is a clinical-stage biotech with no approved products, net losses of $85.2M in 2025, and an accumulated deficit of $265.4M — the IPO provides essential capital but does not change the high-risk, pre-revenue profile.
Key Financial Metrics
Key Facts
- IPO of 16,666,667 shares priced at $18.00/share, raising $300M in gross proceeds
- Net proceeds to company estimated at $279M ($274.2M after offering expenses)
- Underwriters: Morgan Stanley, Jefferies, Evercore ISI, Guggenheim Securities
- Underwriters have 30-day option to purchase up to 2,500,000 additional shares
- Shares to trade on Nasdaq Global Select Market under ticker 'AVLN'
- Pro forma as-adjusted cash + marketable securities: $427.6M
- Net losses of $85.2M (2025) and $49.7M (2024); accumulated deficit of $265.4M
- Proceeds intended to fund AP01 through Phase 2b topline and into Phase 3 (~$150M), AP02 through Phase 2 topline and into Phase 3 (~$90M), and AP03 through Phase 1 (~$10M)
- Company expects cash runway into 2029 based on current operating plan
- Existing stockholders paid a weighted-average price of $15.47/share vs. IPO price of $18.00
Financial Impact
IPO raised $300M in gross proceeds ($279M net to company before expenses); pro forma as-adjusted cash + marketable securities of $427.6M
Risk Factors
- No approved products or revenue; entirely dependent on clinical trial success
- Net losses of $85.2M in 2025 and accumulated deficit of $265.4M
- Clinical-stage risk: AP01 and AP02 Phase 2 data not expected until H2 2027 and late 2027 respectively
- Novel inhaled formulation approach for pulmonary fibrosis has no approved precedent
- Dilution: new investors paid $18.00/share vs. existing holders' weighted-average of $15.47
- Substantial additional capital likely needed beyond IPO proceeds to reach commercialization
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 424B4 Filing (Primary) | 0001193125-26-197686 |
| Document: 0001193125-26-197686-index-headers.html | 0001193125-26-197686 |
| Document: 0001193125-26-197686-index.html | 0001193125-26-197686 |
| Document: 0001193125-26-197686.txt | 0001193125-26-197686 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 21, 2026 5w ago | Press Release | $31.62 $28.32 | ▼ −10.44% | ▼ −9.42% | $25.83 (−18.31%) |
Aug 16, 2026 10w ago | Institutional Cluster | $38.25 $37.69 | ▼ −1.46% | ▼ −0.27% | $25.83 (−32.47%) |
Aug 12, 2026 10w ago | 8-K | $37.38 $38.97 | ▲ +4.25% | ▲ +4.70% | $25.83 (−30.90%) |
Aug 12, 2026 10w ago | Press Release | $37.38 $38.97 | ▲ +4.25% | ▲ +4.70% | $25.83 (−30.90%) |
Jun 17, 2026 18w ago | 8-K | $29.31 $30.09 | ▲ +2.66% | ▲ +3.70% | $25.83 (−11.87%) |
Jun 17, 2026 18w ago | Press Release | $29.31 $30.09 | ▲ +2.66% | ▲ +3.70% | $25.83 (−11.87%) |
Jun 3, 2026 20w ago | 8-K | $26.40 $28.53 | ▲ +8.07% | ▲ +11.89% | $25.83 (−2.16%) |
May 5, 2026 25w ago | Press Release | $27.71 $29.90 | ▲ +7.90% | ▲ +6.77% | $25.83 (−6.78%) |
May 1, 2026 25w ago | Insider Cluster | $29.07 $29.57 | ▲ +1.72% | ▼ −1.25% | $25.83 (−11.15%) |
May 1, 2026 25w ago | Insider Cluster | $29.07 $29.57 | ▲ +1.72% | ▼ −1.25% | $25.83 (−11.15%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers